Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far

Patricia A Tang; Michael M Vickers; Daniel Y C Heng

doi:10.1016/j.hoc.2011.04.003

Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far

Hematol Oncol Clin North Am. 2011 Aug;25(4):871-91. doi: 10.1016/j.hoc.2011.04.003.

Authors

Patricia A Tang¹, Michael M Vickers, Daniel Y C Heng

Affiliation

¹ Department of Oncology, Tom Baker Cancer Center, University of Calgary, 1331-29th Street North West, Calgary, Alberta, Canada.

PMID: 21763972
DOI: 10.1016/j.hoc.2011.04.003

Abstract

The current treatment paradigm for metastatic renal cell carcinoma (RCC) includes agents that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. Because these agents have revolutionized RCC over the past five years, new clinical and molecular predictive and prognostic tools are required. These are potentially important for therapy selection, patient counseling, and clinical trial stratification. This review examines clinical prognostic models and molecular biomarkers in RCC.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Biomarkers, Tumor / antagonists & inhibitors
Biomarkers, Tumor / metabolism
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / metabolism
Carcinoma, Renal Cell / pathology
Humans
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / metabolism
Kidney Neoplasms / pathology
Prognosis
Protein Kinase Inhibitors / therapeutic use
TOR Serine-Threonine Kinases / antagonists & inhibitors*
TOR Serine-Threonine Kinases / metabolism
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Vascular Endothelial Growth Factor A / metabolism

Substances

Angiogenesis Inhibitors
Biomarkers, Tumor
Protein Kinase Inhibitors
VEGFA protein, human
Vascular Endothelial Growth Factor A
TOR Serine-Threonine Kinases